GW Pharmaceuticals and its subsidiary Greenwich Biosciences are gearing up to launch Epidiolex in the US after drug enforcement officials re-classified the cannabis-based medicine to the lowest restriction. More: GW Pharma’s Epidiolex nears US launch Source: News
read moreNHS England says it will provide £10 million to GPs to help support delivery of additional extended hours, out of hours and unscheduled care sessions over the winter period. More: NHS England pledges £10m to support GP services over winter
read morePfizer’s pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib has been approved in the US as a treatment for some forms of lung cancer. More: US green light for Pfizer’s lung cancer drug Source: News
read moreBayer’s pharma leader in the Americas is heading off to biotech, but the German drugmaker has a seasoned veteran ready to step up. On Thursday, the company said Sebastian Guth would take over as president of its pharmaceuticals business in
read moreGW Pharma hasn’t been able to launch its cannabidiol drug Epidiolex even after winning historic FDA approval, but with a DEA move this week, the company can plan its rollout. More: GW Pharma, armed with best-case DEA decision, charts path
read moreThe sunshine law that requires drug and medical device manufacturers to report financial relationships with physicians to the U.S. government will expand to nurses and other medical professionals under a finalized bipartisan opioid relief bill that will likely be enacted
read more© 1994 - 2026 B.M. Pharmaceuticals